University Hospitals Leuven
Leuven, 3000, Belgium
NCT Number: NCT00484848
Totally implanted venous access ports allow a safe delivery of medication, mainly chemotherapy, but are also used for blood sampling. This last procedure is not always successful, as it appeared from a nurse's survey in different hospitals in Flanders, including the University Hospitals in Leuven, Belgium. In 3 to 29 percent of the attempts, blood withdrawal is impaired or not possible, as an intermittent or permanent fact. This is in line with international literature data where difficulty in blood draw was noted in 6 to 26% of port accessions. Partial or total occlusion leads to discomfort for the patient, delay in therapy, higher costs and extra nursing time.
A new port system with a tangential outlet (Vortex port) was designed and according to the manufacturer, this shape will allow to cleanse the entire reservoir of the port more efficiently and avoid the formation of precipitates of medication or blood that could lead to an obstruction of the device. These precipitates are also regarded as a potential risk factor for infection.
However, only one previously published small randomised study addressed the value of the Vortex port when compared to conventional access devices: Stevens et al. were able to show a reduction in obstruction incidence from 26% to 7% with the use of the Vortex port. The incidence of blood withdrawal problems in our experience with conventional ports in University hospitals Leuven was 8% thus lower than that reported by Stevens, but this remains the most frequent problem faced by care providers and patients.
With this study, the investigators aim to compare the performance of the tangential outlet ports and that of a "conventional" port in order to assess an eventual functional difference.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Leuven, 3000, Belgium
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: up to a maximum of 6 months after insertion
Time frame: up to a maximum of 6 months after insertion
Time frame: immediately after insertion and up to a maximum of 6 months afterwards
Time frame: up to a maximum of 6 months after insertion
Universitaire Ziekenhuizen KU Leuven
Other
Functional Evaluation of Conventional Venous Access Port (Celsite®) Versus Venous Access Port With Tangential Outlet (Vortex®) : a Prospective Randomized Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00994136
Hematologic Disease, Hematologic Diseases
Leuven, Vlaams-Brabant, Belgium
View Trial DetailsNCT01220011
Anemia, Anemia, Neonatal
Aurora, Colorado, United States
View Trial DetailsNCT00001715
Hematologic Disease, Hematologic Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT03013439
Anemia, Anemia, Hypochromic
Tokyo, Japan
View Trial Details